Sagida Bibi

Sagida Bibi serves as a Postdoctoral Research Assistant within the Department of Paediatrics at the University of Oxford, actively contributing to the Oxford Vaccine Group's global research initiatives. Her work focuses on dissecting cellular immune mechanisms in vaccine responses, particularly investigating T cell dynamics following SARS-CoV-2 vaccination across diverse platforms.

Her core research spans Immunology, Vaccine Development, and Infectious Diseases, with specialized expertise in T Cell Biology and Clinical Trials methodology. Recent investigations include optimizing mRNA and adenoviral vector vaccine dosing intervals, characterizing MAIT cell-mediated reactogenicity, and developing novel assays for pertussis immune monitoring—demonstrating consistent innovation in translational vaccinology.

Analysis of her 2024-2025 publications reveals a cohesive research trajectory centered on cellular immunity: she systematically examines how vaccine scheduling influences T cell quality, integrates innate-adaptive immune crosstalk in adverse reactions, and bridges clinical observations with laboratory immunology to address real-world vaccine challenges.

As a key member of the Oxford Vaccine Group—a world-leading consortium pivotal in the Oxford-AstraZeneca COVID-19 vaccine development—Dr. Bibi contributes to end-to-end research spanning basic immunology, assay development, and large-scale clinical trials across global populations.